Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down - Here's What Happened

Key Points

• Zealand Pharma A/S shares gapped down from $71.49 to $65.74 prior to trading, reflecting an 8.0% decline.
• Research analysts have mixed ratings on the stock, with Zacks lowering it to a "strong sell" while others upgraded it to "strong buy."
• The company reported Q2 earnings of $16.06 EPS, which fell short of analysts' expectations of $16.72 and significant revenue expectations of $9.18 billion.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) shares gapped down prior to trading on Wednesday . The stock had previously closed at $71.49, but opened at $65.74. Zealand Pharma A/S shares last traded at $65.74, with a volume of 110 shares trading hands.

Analyst Upgrades and Downgrades

ZLDPF has been the subject of several research analyst reports. Barclays upgraded Zealand Pharma A/S to a "strong-buy" rating in a research report on Monday, July 7th. Zacks Research downgraded Zealand Pharma A/S from a "hold" rating to a "strong sell" rating in a research report on Friday, August 15th. BNP Paribas raised Zealand Pharma A/S to a "strong-buy" rating in a research report on Tuesday, July 1st. Finally, Wells Fargo & Company raised Zealand Pharma A/S to a "strong-buy" rating in a research report on Thursday, July 24th. Five research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Zealand Pharma A/S presently has an average rating of "Buy".

Zealand Pharma A/S Trading Down 2.5%

The company has a market cap of $4.78 billion, a price-to-earnings ratio of 4.73 and a beta of 0.73. The company has a debt-to-equity ratio of 0.02, a quick ratio of 15.08 and a current ratio of 15.09. The firm has a fifty day moving average price of $60.34 and a 200 day moving average price of $65.57.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last released its quarterly earnings data on Thursday, August 14th. The company reported $16.06 EPS for the quarter, missing the consensus estimate of $16.72 by ($0.66). The company had revenue of $1.43 billion during the quarter, compared to analyst estimates of $9.18 billion. Zealand Pharma A/S had a net margin of 73.90% and a return on equity of 67.06%. As a group, equities analysts predict that Zealand Pharma A/S will post -2.19 EPS for the current fiscal year.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.